Virbac Releases Liquid Atopic Dermatitis Drug
Cyclavance has a 98% acceptance rate among dogs when given orally or with food.
Virbac Corp. has launched Cyclavance, the first FDA-approved liquid cyclosporine for dogs diagnosed with atopic dermatitis.
Cyclavance (cyclosporine oral solution) is a generic version of Elanco Animal Health’s Atopica cyclosporine capsules. The new Virbac prescription drug is indicated for the control of atopic dermatitis in dogs weighing at least 4 pounds.
A liquid drug like Cyclavance is a bonus for pet owners, according to Virbac, which cited the medication’s “greater than 98% acceptance rate by dogs when administered either directly in the mouth or mixed with a small amount of food.”
“Recommending a product that is easy for the client to administer correctly can significantly improve the long-term satisfaction with the treatment,” said Virbac’s marketing and veterinary services director, Cristiano von Simson, DVM, MBA.
The U.S. Food and Drug Administration approved Cyclavance in late October 2020.
According to the agency’s Freedom of Information Summary, the initial daily dose of Cyclavance is 5 mg/kg/day for 30 days.
Did you know a subscription to Today’s Veterinary Business is free to qualified veterinary professionals? All you have to do is sign up here (and renew each year). You also can sign up to receive the Today’s Veterinary Business weekly e-newsletter.